IN THE SPOTLIGHT

FDA Approves Tepotinib for Metastatic NSCLC

FDA Approves Tepotinib for Metastatic NSCLC

Repotrectinib for ROS1 Fusion–Positive Advanced NSCLC

Repotrectinib for ROS1 Fusion–Positive Advanced NSCLC

Dr Rodriguez on Treating Patients With Lung Cancer Harboring Multiple Actionable Mutations

Dr Rodriguez on Treating Patients With Lung Cancer Harboring Multiple Actionable Mutations

FDA approval makes Enhertu an option for multiple tumour indications

FDA approval makes Enhertu an option for multiple tumour indications

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

The Rise of ADC Anticancer Drugs: Enhertu Sparks Global Craze and Competition in the Pharmaceutical Industry

The Rise of ADC Anticancer Drugs: Enhertu Sparks Global Craze and Competition in the Pharmaceutical Industry

FDA Expands Enhertu Indication to HER2-Positive Solid Tumors

FDA Expands Enhertu Indication to HER2-Positive Solid Tumors

FDA grants accelerated approval to Enhertu for adults with advanced solid tumors

FDA grants accelerated approval to Enhertu for adults with advanced solid tumors

AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod

AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod

Understanding ADC Mechanism of Action Enhances Personalized Medicine in NSCLC

Understanding ADC Mechanism of Action Enhances Personalized Medicine in NSCLC